RE:RE:Latest Corporate Presentation (Nov 27,2024).Eoganacht you are right, strange but not surprising..
As we speak TLT has more than enough patients treated to satisfy the FDA pre-BTD data clarifications request, and BTD approval(no rush to get more patients treated for now).
If you look at the 1Q2025 objectives,
'' Achieving Break Through Designation approval from the FDA''. My take on this, is that the priority for TLT right now, is keeping the little money they have for getting the BTD approval, which will be more beneficial for TLT on the short term.
Getting BTD approval will also bring the SP to a higher level were the financing to complete the 25 patients will be done at a higher SP(less dilution).
Personally, I agree TLT giving priority for now to BTD approval is a very good move.
I also think that TLT choosing to give priority to BTD approval is because TLT is convinced that they will get the FDA BTD approval shortly.
Eoganacht wrote: Thanks for the link to the new corporate presenttion wildbird1. I am quite puzzled by a line on pg. 3
Theralase Strategic Objectives 2Q2025 to 4Q2025
• Enroll 25 remaining patients in Phase II bladder cancer registration clinical study (“Study II”) (75 patients enrolled and treated to date)
Does this mean Theralase doesn't plan on treating any patients in the next 4 months?
Maybe they will clarify tomorrow morning...
wildbird1 wrote: Theralase Corporate Presentation - 11 27 2024 (002) - Adobe cloud storage Page 17....
Is it just me or the CR% at 450 days is still at 43.6%CR.
As I said before Ruvidar is 130% more potent than Merck best treatment Keytruda(18.9%CR at 450 days), and Keytruda doesn't even treat immuno-deficients patients.
Watch out Merck, TLT-Ruvidar is coming!
A word of advice for Merck, talk to Dr.Lbiati while you still can.
I love my TLT shares.